On April 22, 2026 Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, reported the nationwide availability of Agilent Technologies’ PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck’s KEYTRUDA.i KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer.ii

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Helping Patients Access Critical New Treatment Options
Approximately 80% of individuals with ovarian cancer experience recurrence after initial therapy, and many develop resistance to platinum-based chemotherapy, leading to limited treatment options and poor survival outcomes. The approval of KEYTRUDA and KEYTRUDA QLEX in this setting introduces meaningful new treatment options that have been found to reduce the risk of disease progression and improve overall survival.iii Labcorp’s nationwide availability of PD-L1 IHC 22C3 pharmDx enables clinicians to quickly identify patients who may benefit from these newly approved treatments.

"Platinum-resistant ovarian cancer is incurable, and current treatment options offer limited and short-lived benefits for patients—making it one of the most challenging forms of the disease to treat," said Dr. Marcia Eisenberg, Ph.D., chief scientific officer at Labcorp. "By making this companion diagnostic available nationwide, Labcorp is helping clinicians rapidly identify eligible patients and connecting them with a therapy that offers new hope."

Supporting Early Access Following FDA Approvals
Following the FDA’s February approval of KEYTRUDA and KEYTRUDA QLEX alongside PD-L1 IHC 22C3 pharmDx,ii Labcorp participated in Agilent Technologies’ Early Validation Program to help support rapid testing availability. Through standardized training and readiness activities, Labcorp was prepared to expand nationwide access quickly following approval.

(Press release, LabCorp, APR 22, 2026, View Source [SID1234664682])

On April 22, 2026 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that its research collaborators’ abstract has been selected for publication at the upcoming 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place May 29 – June 2, 2026 in Chicago, Illinois. The abstract details positive clinical data from studies of predictive biomarkers in patients receiving its lead drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), for the treatment of lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to be selected for publication at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting, one of the leading medical meetings for physicians and oncology professionals caring for people with cancer," said Ryan Confer, President and Chief Executive Officer at Genprex. "We are also excited to share our latest research on predictive biomarkers that may help enrich our lung cancer clinical trials. We believe this research may help predict patient response to REQORSA treatment, which could lead to improved patient outcomes."

The featured Genprex-supported abstract at ASCO (Free ASCO Whitepaper) 2026:

Title: "Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid"

Abstract Number: e15184

About Reqorsa Gene Therapy

REQORSA Gene Therapy (quaratusugene ozeplasmid) decreases tumor glucose metabolism, interrupts cell signaling pathways that cause replication and proliferation of cancer cells, targets and kills cancer cells, and stimulates the natural immune responses against cancer. It re-expresses TUSC2 protein in the cell and also increases the anti-tumor immune cell population and down-regulates PD-L1, thereby potentially boosting the immune response to cancer.

REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form, which has a positive charge. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing uptake by normal tissue. REQORSA is injected intravenously and specifically targets cancer cells. Cancer cells have elevated metabolism compared to healthy cells and as a result, are negatively charged compared to healthy cells, which are generally charge neutral. Thus, there is an electrostatic attraction of REQORSA to cancer cells. Cancers also have a leaky vasculature, so REQORSA leaks out of the blood vessels and can be taken up by cancer cells, which have a greater rate of pinocytosis (uptake of extracellular material) than normal cells. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells. Biopsies in three patients with NSCLC treated with REQORSA show major increases in TUSC2 protein expression in the tumor cells one day after REQORSA administration. We believe that REQORSA is the first systemic gene therapy to be used for cancer in humans.

(Press release, Genprex, APR 22, 2026, View Source [SID1234664680])

On April 22, 2026 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, reported that updated clinical data from its Phase 1/2 study of CRB-701, a next generation Nectin-4 ADC, in both head and neck squamous cell carcinoma (HNSCC) and cervical cancer will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to be held May 29 – June 2 in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data will include clinical response durability as well as HNSCC patient subgroup analysis. Corbus previously presented dose optimization data from the study, including encouraging efficacy and safety findings, at the 2025 European Society for Medical Oncology Congress (ESMO 2025).

Oral Presentation
A phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer – (Tudor-Eliade Ciuleanu, MD, PhD, Arensia Research Clinic; Dominique Berton, MD, Institut de Cancérologie de l’Ouest; et al)

Presenter: Professor Yohann Loriot, Gustave Roussy (Paris)
Session Date and Time: May 29, 4:57 PM CDT
Session Title: Gynecological Cancer
Abstract #: 5508

Poster Presentation:
A phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma – (Charlene Mantia, MD, Glenn J Hanna, MD; Dana Farber, et al)

Presenter: Charlene Mantia, MD, Dana Farber Cancer Institute (Boston)
Session Date and Time: May 30, 4:30 PM CDT
Session Title: Head and Neck Cancer
Abstract #: 6062
Poster Board: 519

The abstracts will be available on the ASCO (Free ASCO Whitepaper) website on May 21, 2026 at 5:00 p.m. ET.

Corbus expects to initiate a registrational study for CRB-701 in second-line HNSCC in mid-2026.
Corbus also anticipates reporting data with CRB-701 in combination with Keytruda in first-line HNSCC patients in Q4 2026 to support potential further registration-enabling trials.

About CRB-701
CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. The FDA has granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer. CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. China.

(Press release, Corbus Pharmaceuticals, APR 22, 2026, View Source [SID1234664679])

On April 22, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene Expression Engineering Facility at Moffitt Cancer Center, will be presenting at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, being held May 6 – 9, 2026, in Dublin, Ireland.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ms. Cox’s presentation, titled "Phase 1 clinical trial of autologous T cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer," will discuss the clinical trial design and objectives, as well as the current status of Anixa’s ongoing Phase 1 clinical trial of lira-cel.

The ISCT 2026 Annual Meeting will bring together thousands of global experts in cell and gene therapy. This event is recognized as the largest conference focused on translating cell and gene therapies from research to clinical practice. The four-day program will feature hundreds of speakers, cutting edge scientific presentations, and interactive sessions covering advances in areas such as gene editing, bioprocessing, and clinical translation, alongside extensive networking opportunities and industry showcases.

About Lira-cel, Anixa’s CAR-T Therapy for Recurrent Ovarian Cancer
Liraltagene autoleucel, or lira-cel, uniquely targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells, tumor vasculature, and certain cancer cells, but not in healthy tissue. The ongoing Phase 1 trial (ClinicalTrials.gov NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies.

(Press release, Anixa Biosciences, APR 22, 2026, View Source [SID1234664678])

On April 22, 2026 ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), reported the dosing of patients with its first-in-class tetraspecific T-cell engager, MDX2003, for relapsed or refractory B-cell lymphoma. This multispecific antibody targets two proteins found on the surface of B-cell malignancies, CD19 and CD20, along with the CD3 and CD28 co-stimulatory T-cell activators to sustain T cell killing of these tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The MDX-2003-101 study (NCT07249905) is designed to evaluate the safety, tolerability, pharmacokinetic, and immune activity of MDX2003 in adult patients with various types of B-cell lymphoma. The study includes dose-escalation and dose-expansion phases. B-cell lymphoma, a form of non-Hodgkin lymphoma arising from B lymphocytes, represents the most common lymphoma subtype, accounting for approximately 85% of cases1. Despite available therapies, an estimated 30–40% of patients experience disease relapse, progression, or refractory disease following initial chemoimmunotherapy2.

"This clinical trial represents a significant milestone for ModeX," said Giovanni Abbadessa, M.D., Ph.D., Chief Medical Officer of ModeX Therapeutics. "MDX2003 is designed to address limitations of current T‑cell-engagers by combining dual tumor antigen targeting with optimized T‑cell activation. This first‑in‑human study will allow us to assess safety and biologic activity in patients with advanced B‑cell lymphoma."

Preclinical proof-of-concept data, along with analyses supporting clinical dose selection, were presented in poster presentations at the 2025 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and ESMO (Free ESMO Whitepaper) Targeted Anticancer Therapies Congress 2026.

"MDX2003 takes advantage of our proprietary multispecific antibody design to optimize tumor killing and address the problem of immune escape in the treatment of lymphoma," said Phillip Frost, M.D., Chairman and CEO of OPKO Health, and Gary Nabel, M.D., Ph.D., President and CEO of ModeX and Chief Innovation Officer of OPKO Health. "This study will define dosing and treatment regimens for future efficacy trials."

About MDX2003

MDX2003 is a novel tetraspecific T-cell engager targeting CD19 and CD20 on B cells and CD3 and CD28 on T cells. This dual B-cell targeting strategy is intended to mitigate the impact of tumor antigen loss, while CD3/CD28 co-stimulation aims to promote robust T-cell activation, survival, and sustained cytotoxic activity. Preclinical studies have demonstrated potent anti-tumor activity and balanced T-cell activation, supporting advancement into clinical evaluation.

(Press release, Opko Health, APR 22, 2026, View Source [SID1234664677])